Convert Optimism OP to VitaStem VITASTEM

Optimism is a network of chains called the Superchain, built on the open-source OP Stack. OP Mainnet was the first chain, with several others now operating on the OP Stack architecture, including Base (by Coinbase), Unichain (by Uniswap), Ink (by Kraken), and World Chain (by Worldcoin). The OP Stack serves as a framework for Ethereum Layer 2 chains and supports significant L2 activity. Every OP Chain in the Superchain contributes back to the Optimism Collective and all chains follow a standardized revenue-sharing model: the greater of 2.5% of total chain revenue or 15% of onchain profit (defined as fees minus L1 gas costs) is paid back to the Optimism. By aligning economic incentives across many chains, Optimism aims to transform Ethereum scaling into a sustainable flywheel by delivering fast, low-cost transactions while reinvesting in the future of the ecosystem. OP holders participate in governance to shape protocol upgrades, funding decisions, and more

VitaSTEM — The first AI-enabled longevity project and inaugural IP-Token launched by Aubrai, VitaDAO’s decentralized scientific agent. After six months of deep research on public and proprietary single-cell RNA-seq and multi-omics datasets, our scientific research team analyzed more than 850,000 human hematopoietic stem cell transcriptomes from donors aged 23–91 (both male and female). This effort uncovered 100+ high-potential rejuvenation target genes and revealed critical drivers of decline such as RhoA hyperactivation, CD38 upregulation, and CCR9 downregulation. Rather than treating HSC aging as a single defect, Aubrai recognized it as convergent damage across interconnected systems, generating a comprehensive multi-modal, five-phase rejuvenation protocol targeting transcriptional stress, metabolic dysfunction, and epigenetic drift in parallel. The agent shortlisted target genes using insights from thousands of peer-reviewed publications and private data and also optimized experimental protocols to guide in vitro and upcoming pre-clinical testing. For the first time, human researchers and AI Agents collaborate as co-scientists in the creation of pioneering scientific IP.